Allos Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

20.04.12	Allos Therapeutics Announces Outcome of Request for Re-examination of CHMP Opinion for FOLOTYN® in Europe (Businesswire)
05.04.12	Wall Street Schluss: US-Börsen schliessen kaum verändert, Bed Bath Beyond legen nach Zahlen kräftig zu (Aktiencheck)
05.04.12	Wall Street Update: US-Börsen kaum verändert, Bed Bath Beyond nach Zahlen gefragt (Aktiencheck)
05.04.12	Wall Street Eröffnung: Verluste, Arbeitsmarktdaten und März-Umsätze im Blick, Constellation Brands knicken ein (Aktiencheck)
05.04.12	Allos Therapeutics-Aktie nach Übernahme durch Spectrum Pharmaceuticals im Fokus (Aktiencheck)
06.03.12	Allos Therapeutics Reports Fourth Quarter and Full Year 2011 Financial Results (Businesswire)
21.02.12	Allos Therapeutics to Report Fourth Quarter and Full Year 2011 Results on March 6, 2012 (Businesswire)
30.01.12	Allos Therapeutics Requests Re-Examination of CHMP Opinion on FOLOTYN® in PTCL at the European Medicines Agency (Businesswire)
30.01.12	Allos Therapeutics Announces Interim Results from Phase 1 Combination Study of FOLOTYN® and Bexarotene Demonstrate Activity in Patients with Relapsed or Refractory Cutaneous T-cell Lymphoma (Businesswire)
20.01.12	Allos Therapeutics Receives Negative Opinion from the CHMP on FOLOTYN (Businesswire)
10.01.12	Allos Therapeutics Reports 2011 Financial Highlights and Key Business Priorities (Businesswire)
21.12.11	Allos Therapeutics Invites Investors to Listen to Webcast of Presentation at J.P. Morgan Healthcare Conference (Businesswire)
30.03.11	UniFirst Announces Financial Results for the Second Quarter and First Half of Fiscal 2011 (Businesswire)
19.01.11	Journal of Clinical Oncology Publishes Results from Pivotal Phase 2 PROPEL Study of FOLOTYN® in Relapsed or Refractory Peripheral T-Cell Lymphoma (Businesswire)
21.12.10	Allos Therapeutics’ Marketing Authorisation Application (MAA) for FOLOTYN® Accepted for Review by European Medicines Agency (EMA) (Businesswire)
09.09.10	Allos Therapeutics Announces FOLOTYN® Data Presentation at the 35th ESMO Congress (Businesswire)
11.06.10	Allos Therapeutics’ FOLOTYN Shows Activity and Tolerability in Phase 1 Dose Finding Study in Patients with Relapsed or Refractory CTCL (Businesswire)
27.04.10	Allos Therapeutics Appoints Dr. Charles Morris as Chief Medical Officer (Businesswire)
07.12.09	Allos Therapeutics’ FOLOTYN™ Demonstrates Activity in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma Treated with Stem Cell Transplant (Businesswire)
04.12.09	Allos Therapeutics Announces an Agreement with Idis for a Named Patient Program for FOLOTYN™ (pralatrexate injection) (Businesswire)
07.07.09	Allos Therapeutics Completes Enrollment in Randomized Phase 2b Trial of Pralatrexate in Patients with Advanced Non-Small Cell Lung Cancer (Businesswire)
26.05.09	Allos Therapeutics Announces FDA Accepts Pralatrexate NDA for Filing and Grants the Application Priority Review Status (Businesswire)
19.04.09	Allos Therapeutics’ Pralatrexate Demonstrates Anticancer Activity in Multiple Cancer Cell Lines (Businesswire)
06.12.08	Two Pralatrexate Studies Presented at the 50th Annual Meeting of the American Society of Hematology (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Givaudan	4’040.00	1.71 %	K V
Geberit	547.80	1.59 %	K V
Part Grp Hldg	1’297.00	1.49 %	K V
ABB	51.94	1.29 %	K V
Swiss Life Hldg	691.80	1.26 %	K V
Zurich Insur Gr	548.00	-0.18 %	K V
Kuehne+Nagel Int	210.90	-0.33 %	K V
Swiss Re	128.20	-0.66 %	K V
Sonova Hldg	293.00	-0.85 %	K V
Novartis	87.94	-0.92 %	K V

Nachrichten zu Allos Therapeutics Inc.

Aktien Top/Flop

Meistgelesene Nachrichten